PERSPECTIVES: Protelos® for postmenauposal osteoporotic patients with previous therapies

PERSPECTIVES: Protelos® for postmenauposal osteoporotic patients with previous therapies - an observational prospective multi-centre study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN80637249

Enrollment

2250

Registered

2009-05-15

Start date

2009-02-02

Completion date

Unknown

Last updated

2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal osteoporosis Musculoskeletal Diseases Osteoporosis without pathological fracture

Interventions

1. To get information on the evolution of osteoporosis therapy in the treatment postmenopausal osteoporosis via standardised documentation 2. To get information on comobidity and comed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Postmenopausal osteoporotic women, treated with strontium ranelat (Protelos®).

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
1. Efficacy under routine conditions: ordinal scale (very good, good, moderate, bad) 2. Tolerability: ordinal scale (very good, good, moderate, bad) 3. Pain (VAS; 0 = no pain - 10 = unbearable pain) 4. Fractures (standardized documentation) 5. Quality of life (patients questionnaire including 9 questions = ordinal scale) 6. Compliance, persistence, adherence (standardised patients questionnaire) All data will be assessed at initiation visit and 3 months later at final visit.	—

Measure

Time frame

1. Efficacy under routine conditions: ordinal scale (very good, good, moderate, bad) 2. Tolerability: ordinal scale (very good, good, moderate, bad) 3. Pain (VAS; 0 = no pain - 10 = unbearable pain) 4. Fractures (standardized documentation) 5. Quality of life (patients questionnaire including 9 questions = ordinal scale) 6. Compliance, persistence, adherence (standardised patients questionnaire) All data will be assessed at initiation visit and 3 months later at final visit.

—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026